Cost‐benefit evaluation of a new technology for treatment of peptic ulcer disease
作者:
Morton L. Paterson,
期刊:
Managerial and Decision Economics
(WILEY Available online 1983)
卷期:
Volume 4,
issue 1
页码: 50-62
ISSN:0143-6570
年代: 1983
DOI:10.1002/mde.4090040108
出版商: John Wiley&Sons, Ltd.
数据来源: WILEY
摘要:
AbstractPsychosocial benefit resists monetary expression. However, reduction in costs, with no loss of benefits assumed, improves a cost‐benefit ratio. The effect of cimetidine on the costs of ulcer has been widely studied. Randomized clinical trials show reductions in surgery and work loss among cimetidine‐treated patients versus placebo controls. In the community, time series studies have documented drops in ulcer surgery, averaging about 25% below the expected trend line, following marketing introduction of the drug. These, plus a cross‐sectional study of Medicaid patients with and without use of cimetidine, indicate that the drug has reduced the net direct costs of ulcer di
点击下载:
PDF
(936KB)
返 回